Clinical trials: Advanced Tumor
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
The primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT04401800
- Testing
- Lenvatinib, Tislelizumab
- Where
- 9 sites in China
- Volunteers
- 64 people
- Sponsor
- BeiGene
Advanced Solid Tumors, Lymphoma
Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma
This study is being conducted to evaluate the safety profile and the Maximum Tolerated Dose (MTD) of TAK-901 in adult patients with advanced solid tumors or lymphoma.
- Trial name
- NCT00935844
- Testing
- TAK-901
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Cancer, Metastatic Cancer
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumors
- Trial name
- STMN1-LP (NCT01505153)
- Testing
- pbi-shRNA STMN1 LP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gradalis, Inc.
Advanced Cancer
A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
This is a Phase 1 study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and capecitabine.
- Trial name
- NCT00710736
- Testing
- ARRY-334543, EGFR/ErbB2 inhibitor; oral, Capecitabine, 5-fluorouracil prodrug; oral
- Where
- 4 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Malignant Solid Tumour, Ovarian Cancer
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Overall Design: This is a multicenter, open-label, Phase 1/2 study which will be conducted in three arms (as described below). Each arm will be conducted in two parts: a Phase 1 part which will include dose escalation and a Phase…
- Conditions
- Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma
- Trial name
- NCT01618136
- Testing
- E7449 alone, E7449 plus TMZ, E7449 plus carboplatin and paclitaxel
- Where
- 2 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- Eisai Limited
Advanced Solid Tumors
A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)
This is a single-arm and open-label study of ATG-008 for the Treatment of Patients With advanced Solid Tumors harboring NFE 2L2, STK11, RICTOR or other specific genetic alterationts
- Trial name
- NCT04518137
- Testing
- ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle
- Where
- 4 sites in China
- Volunteers
- 5 people
- Sponsor
- Shanghai Antengene Corporation Limited
Advanced Solid Tumord
Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors
This is a two-part study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ107 in Chinese patients with advanced solid tumors.
- Trial name
- NCT04001075
- Testing
- TJ107
- Where
- 4 sites in China
- Volunteers
- 32 people
- Sponsor
- TJ Biopharma Co., Ltd.
Basal Cell Carcinoma
A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)
This prospective, observational, cohort study is designed to assess the effectiveness and safety outcomes of vismodegib and to assess actual day-to-day disease and participant management by the physician.
- Trial name
- ROSETT (NCT02371967)
- Testing
- Vismodegib
- Where
- 4 sites in Sweden
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Advanced (Unresectable or Metastatic) Melanoma
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced…
- Trial name
- NCT07221734
- Testing
- MB11 (Proposed Nivolumab Biosimilar), EU-Opdivo®, US- sourced Opdivo®
- Where
- 86 sites in Bosnia and Herzegovina, Brazil and 11 more
- Volunteers
- 632 people
- Sponsor
- mAbxience Research S.L.
Advanced or Metastatic Solid Tumors
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Study DCBY02-101 is a multicenter, open-label, Phase 1 study to assess the effects of anti-CD93 mAb (DCBY02) as a monotherapy in patients with advanced or metastatic solid tumors.
- Trial name
- NCT05496595
- Testing
- DCBY02
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- DynamiCure Biotechnology
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in…
- Conditions
- Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
- Trial name
- NCT07262619
- Testing
- EIK1005, pembrolizumab (KEYTRUDA® )
- Where
- 45 sites in United States, Australia and 13 more
- Volunteers
- 160 people
- Sponsor
- Eikon Therapeutics
Head and Neck Squamous Cell Carcinoma, Oral Mucositis
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
The proposed study in patients with previously untreated locally advanced head and neck squamous cell carcinoma (HNSCC) is designed to evaluate the efficacy and safety of three different doses of MIT-001 compared to the placebo…
- Trial name
- MIT-001 (NCT04651634)
- Testing
- MIT-001 plus CCRT
- Where
- 16 sites in United States, South Korea
- Volunteers
- 60 people
- Sponsor
- MitoImmune Therapeutics
Advanced Solid Tumors, Lymphoma
KN046 in Subjects With Advanced Solid Tumors and Lymphoma
This is a phase Ia/Ib, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN046 in subjects with advanced solid tumors and lymphoma .
- Trial name
- NCT03733951
- Testing
- KN046
- Where
- 13 sites in China
- Volunteers
- 139 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or…
- Trial name
- NCT06271837
- Testing
- Trastuzumab deruxtecan, Bevacizumab
- Where
- 29 sites in China
- Volunteers
- 127 people
- Sponsor
- AstraZeneca
Advanced Malignant Solid Tumor
PRL3-Zumab in Patients With Advanced Solid Tumors
This is a multicenter, Phase II, open-label, single-dose-level (6 mg/kg) study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumors.
- Trial name
- China Phase II (NCT07541001)
- Testing
- PRL3-ZUMAB
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Intra-IMMUSG Pte Ltd
Pancreatic Cancer
A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer
The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic…
- Trial name
- NCT00051467
- Testing
- TNFerade
- Where
- 25 sites in United States
- Sponsor
- GenVec
Advanced Solid Tumor
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
The study was conducted in two periods, Period 1 (mass balance) and Period 2 (extension). The purpose of Period 1 of this study was to provide a quantitative characterization of the mass balance, rates and routes of elimination…
- Trial name
- NCT05246111
- Testing
- [14C]Berzosertib, Berzosertib, Topotecan
- Where
- 2 sites in Hungary
- Volunteers
- 6 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Advanced Cancer
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK105 as a single agent in adult subjects with advanced solid tumor malignancies.
- Trial name
- NCT03352531
- Testing
- AK-105
- Where
- 5 sites in Australia
- Volunteers
- 99 people
- Sponsor
- Akesobio Australia Pty Ltd
Gastric Cancer
Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer
The purpose of the study is to verify non-inferiority of survival time between Isovorin/5-fluorouracil (1-LV/5FU) therapy and TS-1 therapy in patients with inoperable advanced or recurrent gastric cancer.
- Trial name
- NCT00195572
- Testing
- Isovorin, TS-1
- Where
- 43 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neoplasms
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.
- Trial name
- NCT02588612
- Testing
- letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.